Clinical trials: Bevacizumab
Healthy
To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed Avastin
This study is a Phase 1 Randomized, Double-blind, Three-arm, Parallel Group, Single-dose Study to compare the PK, safety and immunogenicity of the proposed biosimilar test product CT-P16 with EU-approved Avastin and US-licensed…
- Trial name
- NCT03247673
- Testing
- CT-P16, EU-approved Avastin, US-licensed Avastin
- Where
- 3 sites in South Korea
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- Celltrion
Breast Cancer
Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer
The main purpose of this study is to find out what effects taking the drug bevacizumab together with two chemotherapeutic agents, docetaxel and cyclophosphamide followed by doxorubicin alone before surgery will on breast cancer.
- Trial name
- NCT00203502
- Testing
- Bevacizumab, Cyclophosphamide, Docetaxel
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Healthy
A Study to Compare Pharmacokinetic and Safety of TRS003 to China-approved Bevacizumab and US-licensed Avastin®
This is a 12-week, randomized, double-blind, single-dose pharmacokinetic (PK) study. Approximately 114 healthy male participants (screening occurred within 28 days prior to dosing) will be randomized 1:1:1 to either TRS003…
- Trial name
- NCT03882424
- Testing
- TRS003, China-approved Bevacizumab, US-licensed Avastin
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
Pterygium
Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery
This study will evaluate the efficacy and safety of the use of bevacizumab (Avastin) as an adjunctive medication during pterygium surgery in preventing pterygium recurrence.
- Trial name
- NCT01115517
- Testing
- Bevacizumab, Mitomycin C
- Where
- 2 sites in United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Healthy Volunteers
Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers
Randomized, double blind, parallel group, single dose, 3 arm study to investigate and compare the pharmacokinetics (PK), safety and immunogenicity profile of MB02 with US and EU Avastin® in healthy male subjects.
- Trial name
- NCT04238663
- Testing
- MB02 (Bevacizumab Biosimilar), EU approved Avastin®, US licenced Avastin®
- Where
- Germany
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- mAbxience Research S.L.
Healthy Volunteers
To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects
The purpose of this study is to compare the pharmacokinetics, as well as to evaluate the safety, tolerability and immunogenicity of HD204, US-Avastin and EU-Avastin in healthy male subjects after intravenous administration of a…
- Trial name
- NCT03390673
- Testing
- HD204, Avastin
- Where
- 2 sites in New Zealand
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Prestige Biopharma Limited
Healthy Volunteers
A Study Comparing the Pharmacokinetic Similarity of MB02-SP, MB02-DM and US Licensed-Avastin®.
Randomized, double blind, parallel group, single dose, 3 arm study to investigate and compare the PK, safety and immunogenicity profile of MB02-DM with MB02-SP and US-Avastin® in healthy male subjects.
- Trial name
- NCT04408989
- Testing
- MB02-SP, MB02-DM, US licenced Avastin®
- Where
- 2 sites in New Zealand
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- mAbxience Research S.L.
Rectal Cancer
Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer
Preoperative chemoradiation leads to increased pelvic control and overall survival, but both distant and local disease control remain problematic in locally advanced rectal cancer patients.
- Trial name
- NCT00113230
- Testing
- Avastin (Bevacizumab, RHUMAB VEGF), Capecitabine, Radiation Therapy
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to determine whether the combination of bevacizumab and bortezomib have increased efficacy in the treatment of relapsed/ refractory multiple myeloma.
- Trial name
- NCT00464178
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Hackensack Meridian Health
Non-Ischemic Central Retinal Vein Occlusion
Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion
This is a study designed to determine if the addition of Ozurdex® to bevacizumab (Avastin®) eye injections reduces the need for repeat bevacizumab eye injections in patients with nonischemic central retina vein occlusion.
- Trial name
- NCT01295112
- Testing
- Active bevacizumab and Active dexamethasone
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Texas Retina Associates
Healthy
Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male
To confirm the PK similarity of IBI305 and bevacizumab in healthy volunteers .
- Trial name
- NCT03083990
- Testing
- IBI305(Bevacizumab Biosimilar), Avastin(Bevacizumab)
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC
ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma
ETOP 15-19 ABC-lung is an international, multi-centre open-label, randomized phase II trial with two non-comparative parallel arms of atezolizumab plus bevacizumab with carboplatin-paclitaxel (Arm A) or atezolizumab, bevacizumab…
- Trial name
- ABC-lung (NCT04245085)
- Testing
- Atezolizumab, Bevacizumab, Carboplatin
- Where
- 18 sites in Germany, Singapore and 3 more
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- ETOP IBCSG Partners Foundation
Retinal Vein Occlusion, Macular Edema
A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema
This retrospective data review study will evaluate anti-VEGF injections for retinal vein occlusion (RVO) or diabetic macular edema (DME).
- Trial name
- NCT01918371
- Testing
- Anti-VEGF
- Where
- United States
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Allergan
Retinal Vein Occlusions
Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion
Comparative study to see if treating with Osurdex in addition to Avastin in patients with retinal vein occlusions helps increased visual acuity outcomes
- Trial name
- NCT01085734
- Testing
- Avastin, Osurdex
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Maturi, Raj K., M.D., P.C.
Lymphoma
Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma
Phase II Study of Avastin Plus Rituximab for Patients with Relapsed and Chemotherapy - or Rituxan Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma.
- Trial name
- NCT00081861
- Testing
- Avastin, Rituximab
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Pharmacokinetics, Safety Issues
A Phase I Study Comparing Pharmacokinetics and Safety of Bevacizumab
The aim of the Clinical study is to evaluate the pharmacokinetic and safety profile of a new formulation of Bevacizumab (Zutrab®, Argentinian origin) when compared to two already marketed formulations of Bevacizumab Avastin®…
- Trial name
- NCT03919448
- Testing
- Bevacizumab
- Where
- Argentina
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Diabetic Macular Edema
IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab
This is a phase 4 prospective, nonrandomized, open label, interventional clinical trial. Study eyes will receive 5 required initial monthly Intravitreal Aflibercept (IAI) doses of 2 mg followed by 2q8 IAI for a total of 52 weeks…
- Trial name
- ROTATED (NCT03340610)
- Testing
- Alflibercept
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Southeast Retina Center, Georgia
Endometrial Carcinoma
Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer
The purpose of this study is to find out whether the addition of a drug called Avastin (avastin) to the two-drug combination of carboplatin and paclitaxel shrinks tumors better than the two-drug combination alone in the treatment…
- Trial name
- NCT00879359
- Testing
- carboplatin, paclitaxel, and bevacizumab
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Healthy
Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects
Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of Bevacizumab
- Trial name
- NCT02453672
- Testing
- SB8, EU sourced Avastin®, US Sourced Avastin®
- Where
- Belgium
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Samsung Bioepis Co., Ltd.
Healthy Volunteers, Male
A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male Volunteers
A Randomised, Double Blind, Two-Arm, Single Dose, Parallel Phase I Study To Compare the Pharmacokinetics, Safety and Immunogenicity of MB02 (a Proposed Bevacizumab Biosimilar Drug) and EU Approved Avastin® in Japanese Healthy…
- Conditions
- Healthy Volunteers, Male, Japanese
- Trial name
- NCT04238650
- Testing
- MB02 (Bevacizumab Biosimilar), EU approved Avastin®
- Where
- Japan
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- mAbxience Research S.L.